Overcoming Challenges of Implementing Closed System Transfer Device Clinical In-Use Compatibility Testing for Drug Development of Antibody Drug Conjugates.
暂无分享,去创建一个
William Jackson | Shan Jiang | Frankie Petoskey | Stanley C Kwok | S. C. Kwok | Frankie Petoskey | William Jackson | Shan Jiang | S. Kwok | Stanley Kwok
[1] L. Power,et al. ASHP Guidelines on Handling Hazardous Drugs , 2018, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.
[2] Steven Kozlowski,et al. Overlooking subvisible particles in therapeutic protein products: gaps that may compromise product quality. , 2009, Journal of pharmaceutical sciences.
[3] S. Kumagai,et al. Use of a closed system device to reduce occupational contamination and exposure to antineoplastic drugs in the hospital work environment. , 2009, The Annals of occupational hygiene.
[4] Lennart Johansson,et al. Spill and leakage using a drug preparation system based on double-filter technology. , 2008, The Annals of occupational hygiene.
[5] M. Okuda,et al. Impact of closed-system drug transfer device on exposure of environment and healthcare provider to cyclophosphamide in Japanese hospital , 2013, SpringerPlus.
[6] R. Torres,et al. Silicone Oil Microdroplets Can Induce Antibody Responses Against Recombinant Murine Growth Hormone in Mice. , 2016, Journal of pharmaceutical sciences.
[7] P. Bonnabry,et al. Effectiveness of a Closed-System Transfer Device in Reducing Surface Contamination in a New Antineoplastic Drug-Compounding Unit: A Prospective, Controlled, Parallel Study , 2016, PloS one.
[8] A. Turner,et al. Evaluation of a closed-system cytotoxic transfer device in a pharmaceutical isolator , 2016, Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.
[9] C. Ammann,et al. Stability Studies Needed to Define the Handling and Transport Conditions of Sensitive Pharmaceutical or Biotechnological Products , 2011, AAPS PharmSciTech.
[10] A. Al-jedai,et al. Comparison of closed system transfer devices for turnaround time and ease of use , 2018, Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.
[11] M. Slawson,et al. Workplace Contamination with Antineoplastic Agents in a New Cancer Hospital Using a Closed-System Drug Transfer Device , 2007 .
[12] L. Tyler,et al. Using a closed-system protective device to reduce personnel exposure to antineoplastic agents. , 2003, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.
[13] Kiichi Fukui,et al. Effects of Syringe Material and Silicone Oil Lubrication on the Stability of Pharmaceutical Proteins , 2014, Journal of pharmaceutical sciences.
[14] L. Power,et al. Multicenter evaluation of a new closed system drug‐transfer device in reducing surface contamination by antineoplastic hazardous drugs , 2018, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.
[15] K. Gurusamy,et al. Closed-system drug-transfer devices plus safe handling of hazardous drugs versus safe handling alone for reducing exposure to infusional hazardous drugs in healthcare staff. , 2018, The Cochrane database of systematic reviews.
[16] M. Feuilloley,et al. Container-content compatibility studies: a pharmaceutical team's integrated approach. , 2009, PDA journal of pharmaceutical science and technology.
[17] Clifford J. Mallett,et al. Treatment time, ease of use and cost associated with use of Equashield™, PhaSeal®, or no closed system transfer device for administration of cancer chemotherapy to a dog model† , 2017, Veterinary and comparative oncology.
[18] D. K. Sharma,et al. Micro-Flow Imaging: Flow Microscopy Applied to Sub-visible Particulate Analysis in Protein Formulations , 2010, The AAPS Journal.
[19] P. Sessink,et al. Reduction in surface contamination with antineoplastic drugs in 22 hospital pharmacies in the US following implementation of a closed-system drug transfer device , 2011, Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.
[20] P. Sessink,et al. Use of a closed system drug-transfer device eliminates surface contamination with antineoplastic agents , 2013, Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.
[21] D. Lebel,et al. Impact and appreciation of two methods aiming at reducing hazardous drug environmental contamination: The centralization of the priming of IV tubing in the pharmacy and use of a closed-system transfer device , 2014, Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.
[22] S. Singh,et al. An industry perspective on the monitoring of subvisible particles as a quality attribute for protein therapeutics. , 2010, Journal of pharmaceutical sciences.
[23] H. Chan,et al. Cost Analysis of Using a Closed-System Transfer Device (CSTD) for Antineoplastic Drug preparation in a Malaysian Government-Funded Hospital , 2016, Asian Pacific journal of cancer prevention : APJCP.
[24] Stephen F Eckel,et al. Application of the 2015 proposed NIOSH vapor containment performance protocol for closed system transfer devices used during pharmacy compounding and administration of hazardous drugs , 2018, Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.
[25] E. Meade. Use of closed-system drug transfer devices in the handling and administration of MABs. , 2015, British journal of nursing.